Amarin Corporation (AMRN) announced positive results from a clinical study in which Vascepa, an EPA drug, was used to treat about 8,200 patients suffering from cardiovascular diseases. The study named as REDUCE-IT met its primary and secondary endpoints with around 25% relative risk reduction in the treated population. Shares of Amarin skyrocketed 300% in the … Continue reading Amarin shares pump up on positive results from cardiovascular study